Login / Signup

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).

Nicholas C TurnerMelinda L TelliHope S RugoAudrey MailliezJohannes EttlEva-Maria GrischkeLida A MinaJudith BalmañaPeter Andreas FaschingSara A HurvitzAndrew M WardleyColombe ChappeyAlison L HannahMark E Robsonnull null
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Talazoparib exhibited promising antitumor activity in patients with advanced breast cancer and germline BRCA mutation.
Keyphrases
  • phase ii study
  • breast cancer risk
  • dna repair
  • open label
  • locally advanced
  • randomized controlled trial
  • clinical trial
  • dna damage
  • young adults
  • rectal cancer